Business Wire

Velodyne LiDAR Partners with YellowScan for Integrated LiDAR for UAVs


Velodyne LiDAR Inc., the world leader in 3D vision systems for autonomous vehicles, today announced that it is partnering with YellowScan to integrate its VLP-16 Puck and VLP-16 Puck LITE LiDAR sensors into YellowScan’s Surveyor for a turn-key and reliable LiDAR system for demanding UAV applications.

This press release features multimedia. View the full release here:

(Photo: Business Wire)

(Photo: Business Wire)

Real-time LiDAR systems for UAVs are leveraged around the world for industrial and scientific applications, including surveying, civil engineering, archeology, and environmental science, requiring YellowScan’s ultra-compact 3D laser mapping solutions. By combining its LiveStation app with the unbeatable real-time 3D data capture capabilities of Velodyne’s VLP-16 Puck and VLP-16 Puck LITE sensors – both of which feature a 360° horizontal field-of-view (FoV), 100-meter range, and weighing in at just 830 grams and 590 grams, respectively – YellowScan delivers a turn-key Surveyor system that can be mounted to any drone for short-time data processing needs. The result is a real-time in-flight LiDAR monitoring platform, with users able to see how the final map is being generated in real-time during the drone mission, and the basic map datasets available immediately after the mission.

“YellowScan is known for its commitment to providing reliable and easy to use sensing solutions for the UAV industry, which make the VLP-16 Puck sensors an easy choice for the Surveyor system,” said Erich Smidt, Executive Director Europe, Velodyne LiDAR. “The VLP-16 Pucks are some of our newest offerings, with significant effort put into reducing weight while maintaining the resolution and reliability expected of Velodyne’s industry-leading LiDAR sensors.”

“YellowScan Surveyor, the turn-key LiDAR solution integrating Velodyne’s advanced VLP-16 sensor, enables mapping professionals to do more in less time thanks to tremendously high density and accurate measurements acquired from UAVs,” said Tristan Allouis, CTO, YellowScan.

YellowScan will showcase the Surveyor LiDAR system at the Commercial UAV Expo in Las Vegas on October 24-26. The company will also host a standalone demo on October 27 from 10 am to 2 pm at the College of Southern Nevada in Henderson, Nevada, where participants will see what it’s like to launch and recover a UAV equipped with a YellowScan Surveyor. In addition, participants will see how the sensor covers the Area of Interest (AOI) via LiveStation and how to process the files post flight into a point cloud.

About Velodyne LiDAR

Founded in 1983 and headquartered in Silicon Valley, Velodyne is a technology company known worldwide for its real-time 3D LiDAR sensors. The company evolved after founder/inventor David Hall developed the HDL-64 Solid-State Hybrid LiDAR sensor in 2005. Since then, Velodyne LiDAR Inc. emerged as the unmatched market leader of real-time 3D vision systems used in a variety of commercial applications including autonomous vehicles, vehicle safety systems, mobile mapping, aerial mapping, and security. Its products range from the high-performance, surround view Ultra-Puck™ VLP-32, classic HDL-32/64 and cost-effective VLP-16, to the upcoming, hidden Velarray™. Velodyne’s rich suite of perception software and algorithms are the key enablers of its perception systems. Velodyne supports customers from offices in San Jose, Detroit, Frankfurt, and Beijing. For more information, visit

About YellowScan

YellowScan designs, develops, and produces UAV Mapping solutions for professional applications. Fully integrated, ultra-light and easy to use, these highly automated data collection tools are used by customers around the world in fields such as surveying, forestry, environmental research, archeology, corridor mapping, civil engineering and mining. With more than 10 years of field experience, YellowScan is committed to delivering the highest level of performance, reliability and robustness for its solutions. Our platforms are field tested all over the world in multiple environments (tropical forest, bare soil, mountains, rivers, coast lines, open-pit mine, power lines). For more information please navigate to or contact us

Contact information

Velodyne LiDAR Inc.
Andrew Hussey, 408-966-5078
Communications Director

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

Clovis Oncology Initiates Early Access Program for Rucaparib as Treatment and as Maintenance Therapy in Recurrent Ovarian Cancer in Europe23.3.2018 15:52Tiedote

Clovis Oncology, Inc. (NASDAQ:CLVS) today announced the initiation of an early access program in Europe for rucaparib for treatment and as maintenance therapy in recurrent ovarian cancer. The program will be overseen and implemented by Caligor Coghlan, which specializes in early access to medicines. The program, to be known as the Rucaparib Access Program (RAP), will enable participation from certain countries in Europe, where permitted by applicable rules, procedures and regulatory authorities. The RAP protocol allows for rucaparib treatment of an individual patient with third-line or greater BRCA mutant epithelial, fallopian tube, or primary peritoneal ovarian cancer who has platinum-sensitive disease and is unable to tolerate further platinum-based chemotherapy or has platinum-resistant disease and needs treatment with single agent rucaparib. The RAP protocol will also provide access to rucaparib for maintenance therapy of an individual patient with recurrent epithelial ovarian, fal

CHMP Grants Positive Opinion for Clovis Oncology’s Rubraca® (rucaparib) Tablets23.3.2018 15:50Tiedote

Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that the European Union’s (EU) European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a conditional marketing authorization for Rubraca as monotherapy treatment of adult patients with platinum sensitive, relapsed or progressive, BRCA mutated (germline and/or somatic), high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have been treated with two or more prior lines of platinum based chemotherapy, and who are unable to tolerate further platinum based chemotherapy. The European Marketing Authorization application for the treatment indication was based on objective response rate and duration of response results from two multicenter, single-arm, open-label clinical trials, Study 10 and ARIEL2, in women with advanced BRCA mutant ovarian cancer who had progressed after two or more prior chemotherapies. “The recommendation

Janssen Announces Positive CHMP Opinion for JULUCATM▼ (dolutegravir/rilpivirine)23.3.2018 15:46Tiedote

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a Positive Opinion recommending marketing authorisation for JULUCA™ (dolutegravir 50mg [ViiV Healthcare UK Ltd]/rilpivirine 25mg [Janssen Sciences Ireland UC]). Dolutegravir/rilpivirine is a single-pill, two-drug regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults who are virologically suppressed (HIV-1 RNA <50 c/mL) on a stable antiretroviral regimen for at least six months with no history of virological failure and no known or suspected resistance to any non-nucleoside reverse transcriptase inhibitor (NNRTI) or integrase strand transfer inhibitor (INSTI).1 “We are delighted to be one step closer to bringing JULUCA™ to people living with HIV in Europe,” said Mathai Mammen, M.D., Ph.D., Global Head, Janssen Research & Development, LLC. “Building on our 25-year c

Aitheon Executives Educate World Leaders on Benefits, Challenges of AI at the Annual World Government Summit in Dubai23.3.2018 15:00Tiedote

Aitheon, makers of the world’s first blockchain-powered platform to solve real problems by integrating AI, robotics, IoT, human specialists and cryptocurrency, announced today that executives from the company held a series of high-level briefings with world leaders at the Annual World Government Summit in Dubai. Briefings covered the benefits and challenges of AI, and revolutionary new solutions to world challenges made possible by transformative new technologies. (Read the full release at This press release features multimedia. View the full release here: Aitheon founder and CEO, Andrew Archer, and Chief Strategy Officer, Ryan Burleson, were invited to brief leaders at the Summit by Cyrus Hodes, Co-founder and Director of the AI Initiative, an undertaking of the Future Society at Harvard University’s Kennedy School. Archer and Burleson addressed a variety of AI-related topics, including the impact of AI on

ViiV Healthcare Gains CHMP Positive Opinion for Juluca (dolutegravir/rilpivirine) in Europe23.3.2018 14:27Tiedote

ViiV Healthcare, the global specialist HIV company, majority owned by GlaxoSmithKline, with Pfizer Inc. and Shionogi Limited as shareholders, today announced that the European Committee for Medicinal Products for Human Use (CHMP) has issued a Positive Opinion recommending marketing authorisation for Juluca (dolutegravir/rilpivirine) for the treatment of HIV infection in adults who are virologically suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen for at least six months with no history of virological failure and no known or suspected resistance to any non-nucleoside reverse transcriptase inhibitor or integrase inhibitor. The 2-drug regimen comprises dolutegravir 50mg (ViiV Healthcare) and rilpivirine 25mg (Janssen Sciences Ireland UC). Deborah Waterhouse, Chief Executive Officer at ViiV Healthcare commented: “Today is an important milestone for people living with HIV in Europe. It takes us a step closer to offering the first, single-pill, 2-drug regi

Sofinnova Partners Leads SafeHeal’s €6 Million Series a Financing Round23.3.2018 10:00Tiedote

SafeHeal, an early-stage medtech company specialized in digestive surgery and focused on the development of the Colovac device, announces today that it has closed a €6 million Series A financing round led by Sofinnova Partners. Based in Paris, SafeHeal develops an innovative digestive anastomosis protection device, called Colovac, designed to reduce complications and obviate the need for ostomies for colectomy patients. This technology consists of a minimally invasive and fully reversible implant that remains in place until the body’s natural healing and tissue repair processes are complete, for approximately two weeks, after which it is removed. SafeHeal’s device has the potential to radically transform the market while significantly improve patients’ quality of life by enabling them to resume their normal life without having to bear an artificial anus and wear ostomy pouches for several months. About 270,000 colectomy patients receive an ostomy every year in Europe and the USA, repre

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme